Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $49.25 million. The enterprise value is $42.99 million.

Market Cap	49.25M
Enterprise Value	42.99M

Important Dates

The next estimated earnings date is Wednesday, August 12, 2026, after market close.

Earnings Date	Aug 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 12.76 million shares outstanding. The number of shares has increased by 2.25% in one year.

Current Share Class	12.76M
Shares Outstanding	12.76M
Shares Change (YoY)	+2.25%
Shares Change (QoQ)	-0.57%
Owned by Insiders (%)	3.63%
Owned by Institutions (%)	14.15%
Float	10.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	12.61
P/TBV Ratio	14.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.02.

Current Ratio	1.87
Quick Ratio	1.68
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -157.37% and return on invested capital (ROIC) is -101.40%.

Return on Equity (ROE)	-157.37%
Return on Assets (ROA)	-73.31%
Return on Invested Capital (ROIC)	-101.40%
Return on Capital Employed (ROCE)	-482.04%
Weighted Average Cost of Capital (WACC)	17.04%
Revenue Per Employee	n/a
Profits Per Employee	-$994,489
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +24.12% in the last 52 weeks. The beta is 2.33, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	2.33
52-Week Price Change	+24.12%
50-Day Moving Average	3.09
200-Day Moving Average	3.22
Relative Strength Index (RSI)	57.32
Average Volume (20 Days)	207,485

Short Selling Information

The latest short interest is 1.37 million, so 10.72% of the outstanding shares have been sold short.

Short Interest	1.37M
Short Previous Month	1.48M
Short % of Shares Out	10.72%
Short % of Float	12.64%
Short Ratio (days to cover)	5.25

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.61M
Pretax Income	-15.91M
Net Income	-15.91M
EBITDA	-16.59M
EBIT	-16.61M
Earnings Per Share (EPS)	-$1.44

Full Income Statement

Balance Sheet

The company has $6.32 million in cash and $59,076 in debt, giving a net cash position of $6.26 million or $0.49 per share.

Cash & Cash Equivalents	6.32M
Total Debt	59,076
Net Cash	6.26M
Net Cash Per Share	$0.49
Equity (Book Value)	3.45M
Book Value Per Share	0.31
Working Capital	3.28M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.07 million and capital expenditures -$556, giving a free cash flow of -$15.07 million.

Operating Cash Flow	-15.07M
Capital Expenditures	-556
Depreciation & Amortization	16,559
Net Borrowing	n/a
Free Cash Flow	-15.07M
FCF Per Share	-$1.18

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.25%
Shareholder Yield	-2.25%
Earnings Yield	-32.31%
FCF Yield	-30.61%

Analyst Forecast

The average price target for Lantern Pharma is $20.00, which is 418.14% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	418.14%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1